Trillium Therapeutics Stock Forecast, Price & News

+0.08 (+0.68 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume104,439 shs
Average Volume187,229 shs
Market CapitalizationC$1.22 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive TRIL News and Ratings via Email

Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Trillium Therapeutics

Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.90 out of 5 stars

Analyst Opinion: 2.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Trillium Therapeutics (TSE:TRIL) Frequently Asked Questions

What stocks does MarketBeat like better than Trillium Therapeutics?

Wall Street analysts have given Trillium Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Trillium Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Trillium Therapeutics' next earnings date?

Trillium Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Trillium Therapeutics

How has Trillium Therapeutics' stock price been impacted by COVID-19?

Trillium Therapeutics' stock was trading at C$7.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, TRIL stock has increased by 68.0% and is now trading at C$11.81.
View which stocks have been most impacted by COVID-19

What price target have analysts set for TRIL?

0 brokers have issued 12 month price targets for Trillium Therapeutics' shares. Their forecasts range from C$25.00 to C$25.00. On average, they anticipate Trillium Therapeutics' stock price to reach C$25.00 in the next year. This suggests a possible upside of 111.7% from the stock's current price.
View analysts' price targets for Trillium Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Trillium Therapeutics' key executives?

Trillium Therapeutics' management team includes the following people:
  • Dr. Jan Skvarka, Pres, CEO & Director (Age 54, Pay $812.5k)
  • Mr. James T. Parsons C.A., C.P.A., MAcc, CPA-CA, Chief Financial Officer (Age 56, Pay $543.38k)
  • Dr. Robert Uger, Chief Scientific Officer (Age 50, Pay $595.73k)
  • Dr. Penka Petrova, Chief Devel. Officer (Age 53, Pay $553.53k)
  • Dr. Ingmar Bruns M.D., Ph.D., Chief Medical Officer (Age 46, Pay $230k)
  • Benjamin Looker, Gen. Counsel
  • Dr. Rosemary Harrison, Sr. VP of Corp. Devel. & Strategy (Age 38)
  • Dr. Michael G. Hill, Head of Calgary Site
  • Ms. Kathleen Large, Sr. VP - Clinical Operations (Age 61)

Who are some of Trillium Therapeutics' key competitors?

What other stocks do shareholders of Trillium Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Canada Goose (GOOS), Moderna (MRNA), Shopify (SHOP), Square (SQ), Teladoc Health (TDOC), Zoom Video Communications (ZM), Advanced Micro Devices (AMD) and Canadian Natural Resources (CNQ).

What is Trillium Therapeutics' stock symbol?

Trillium Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TRIL."

How do I buy shares of Trillium Therapeutics?

Shares of TRIL and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Trillium Therapeutics' stock price today?

One share of TRIL stock can currently be purchased for approximately C$11.81.

How much money does Trillium Therapeutics make?

Trillium Therapeutics has a market capitalization of C$1.22 billion and generates C$148,000.00 in revenue each year.

How many employees does Trillium Therapeutics have?

Trillium Therapeutics employs 33 workers across the globe.

What is Trillium Therapeutics' official website?

The official website for Trillium Therapeutics is www.trilliumtherapeutics.com.

Where are Trillium Therapeutics' headquarters?

Trillium Therapeutics is headquartered at 2488 Dunwin Dr, MISSISSAUGA, ON L5L 1J9, Canada.

How can I contact Trillium Therapeutics?

Trillium Therapeutics' mailing address is 2488 Dunwin Dr, MISSISSAUGA, ON L5L 1J9, Canada. The company can be reached via phone at +1-416-5950627.

This page was last updated on 6/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.